Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate

Table 1 Clinicopathological and mutational status of three advanced and metastatic GIST patients treated with imatinib meslyate with CR

Patient	1	2	3
Age (yr)	57	45	51
Gender	F	M	F
ECOG	Grade 0	Grade 0	Grade 0
Tumor origin	Jejunum	Stomach	Jejunum
Tumor size (cm)	20	10	10
Previous treatment	Operation	Laparotomy and excisional biopsy	Operation
Resection	R0	R2	R0
Site of tumor recurrence	Liver, locoregional, and peritoneum	Liver, peritoneum, and retroperitoneum	Peritoneum
Interval between previous treatment and recurrence (mo)	15	0	18
Glivec dose/duration (mo)	400/36	400/23	400/36
Side effect Mutation status	Grade II edema Deletion and insertion mutation at codons 563-572 in exon 11	Grade III edema Deletion and insertion mutation at codons 556-557 in exon 11	Grade II edema Insertion AY at codons 502-503 in exon 9
Time to CR (mo)	20	9	26
CT	CR	CR	CR
PET	CR without activity	CR without activity	CR without activity
Duration of response (mo)	16	14	10
Overall survival (mo)	40	24	54
Status	Free of disease	Free of disease	Free of disease

ECOG: Eastern Cooperative Oncology Group; mo: months; CR: complete response; CT: computed tomography; PET: positron emission tomography.